Thrombolytic therapy in Europe: current status

Area of Science:

• Cardiology
• Emergency Medicine
• Pharmacology

Background:

• Thrombolytic therapy is a cornerstone in managing acute myocardial infarction (AMI).
• Early reperfusion of the infarct-related artery is crucial for limiting myocardial damage and preserving left ventricular function.
• European trials have consistently shown reduced mortality with thrombolytic therapy compared to conventional treatments.

Purpose of the Study:

• To review the efficacy and safety of thrombolytic therapy in acute myocardial infarction.
• To evaluate the impact of different thrombolytic agents and administration timings on patient outcomes.
• To highlight advancements in pre-hospital thrombolysis and their effect on reducing mortality.

Main Methods:

• Analysis of early European clinical trials comparing thrombolytic therapy with conventional treatment.
• Review of large-scale studies evaluating tissue plasminogen activator (t-PA) and streptokinase, including the GUSTO study.
• Examination of pre-hospital thrombolysis trials (GREAT, EMIP) using anistreplase (APSAC).

Main Results:

• Early thrombolytic therapy significantly reduces mortality in AMI patients.
• Accelerated t-PA regimens, as seen in the GUSTO study, demonstrated improved survival.
• Pre-hospital administration of anistreplase (APSAC) in GREAT and EMIP trials reduced time to treatment and lowered mortality.
• Benefits of thrombolytic therapy are sustained for at least 5 years.

Conclusions:

• Thrombolytic therapy, especially when administered early and pre-hospital, is a safe and effective treatment for acute myocardial infarction.
• Optimizing drug regimens and emergency response systems can further improve outcomes.
• Ongoing research aims to develop even safer and more potent thrombolytic agents.